15

WHAT IS CLAIMED IS:

- 1. A method for enhancing cell-based immunotherapy comprising administering antigen-presenting cells and a heat shock protein or a heat shock fusion protein to a target site.
- 5 2. The method of claim 1, wherein death of cells has been induced at the target site by irradiation or by administration of a cytotoxic compound.
 - 3. The method of claim 1, wherein a cytotoxic compound is co-administered to the target site.
- 4. The method of claim 1, wherein the antigen-presenting cells include dendritic cells.
 - 5. The method of claim 1, wherein the antigen-presenting cells are purified.
 - 6. The method of claim 1, wherein the heat shock fusion protein contains a tumor associated antigen, a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.
 - 7. The method of claim 1, wherein the target site is a tumor site.
 - 8. The method of claim 7, wherein death of cells has been induced at the target site by irradiation or by administration of a cytotoxic compound.
 - 9. The method of claim 8, wherein the antigen-presenting cells include dendritic cells.
- 20 The method of claim 9, wherein the antigen-presenting cells are purified cells.
 - 11. The method of claim 10, wherein the heat shock protein is Hsp70 and the heat shock fusion protein contains alpha-fetal protein or prostate specific antigen.
- 12. A method for enhancing cell-based immunotherapy comprising
 administering antigen-presenting cells expressing a heat shock protein or a heat shock fusion protein to a target site.
 - 13. The method of claim 12, wherein death of cells has been induced at the target site by irradiation or by administration of a cytotoxic compound.

5

10

15

- 14. The method of claim 12, wherein a cytotoxic compound is co-administered to the target site.
- 15. A method for enhancing cell-based immunotherapy comprising administering antigen-presenting cells to a target site, wherein pre-existing cells at the target site have been manipulated to express a heat shock protein or a heat shock fusion protein.
- 16. The method of claim 15, wherein death of cells has been induced at the target site by irradiation or by administration of a cytotoxic compound.
- 17. The method of claim 15, wherein a cytotoxic compound is co-administered to the target site.
 - 18. An immunogenic composition comprising antigen-presenting cells, a heat shock protein or a heat shock fusion protein, and a pharmaceutically acceptable carrier.
- 19. The immunogenic composition of claim 18, wherein the antigen-presenting cells include dendritic cells.
- 20. The immunogenic composition of claim 19, wherein the antigen-presenting cells are purified.
- 21. The immunogenic composition of claim 20, wherein the heat shock protein is Hsp70 and the heat shock fusion protein contains alpha-fetal protein or prostate specific antigen.
- 20 22. The immunogenic composition of claim 18, wherein the antigen-presenting cells are purified.
 - 23. The immunogenic composition of claim 18, wherein the heat shock fusion protein contains a tumor associated antigen, a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.
- 25 24. The immunogenic composition of claim 18, further comprising a cytotoxic compound.
 - 25. The immunogenic composition of claim 24, wherein the antigen-presenting cells include dendritic cells.

5

10

15

- 26. The immunogenic composition of claim 24, wherein the antigen-presenting cells are purified.
- 27. The immunogenic composition of claim 24, wherein the heat shock fusion protein contains a tumor associated antigen, a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.
- 28. An immunogenic composition comprising antigen-presenting cells expressing a heat shock protein or a heat shock fusion protein, and a pharmaceutically acceptable carrier.
- 29. The immunogenic composition of claim 28, wherein the antigen-presenting cells include dendritic cells.
 - 30. The immunogenic composition of claim 28, wherein the antigen-presenting cells are purified.
 - 31. The immunogenic composition of claim 28, wherein the heat shock fusion protein contains a tumor associated antigen, a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.
 - 32. The immunogenic composition of claim 28, further comprising a cytotoxic compound.
 - 33. The immunogenic composition of claim 32, wherein the antigen-presenting cells include dendritic cells.
- 20 34. The immunogenic composition of claim 32, wherein the antigen-presenting cells are purified.
 - 35. The immunogenic composition of claim 32, wherein the heat shock fusion protein contains a tumor associated antigen, a polypeptides encoded by an oncogene or a fragment thereof, or a tumor suppressor protein or a fragment thereof.